(Q37873973)

24 August 2017

1 reference

title

Radiation therapy and androgen deprivation in the management of high risk prostate cancer (English)

1 reference

adaptive radiation therapy

24 August 2017

main subject

0 references

1 reference

Alan Dal Pra

1

1 reference

24 August 2017

Fabio L Cury

series ordinal

2

1 reference

24 August 2017

Luis Souhami

series ordinal

3

1 reference

24 August 2017

publication date

1 March 2011

1 reference

International Brazilian Journal of Urology

24 August 2017

published in

1 reference

24 August 2017

volume

37

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

161-75; discussion 176-9

1 reference

Who is the average patient presenting with prostate cancer?

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

The relevance of a hypoxic tumour microenvironment in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Analysis of tumor vascularity using three-dimensional power Doppler ultrasound images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Duration of androgen suppression in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Assuring high quality treatment delivery in clinical trials - Results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

A systematic overview of radiation therapy effects in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382011000200003

10.1590/S1677-55382011000200003

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference